Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359081 | 1.00 | MAP2K1 (0.35) | MAP2K1CSNK2A1RORCHTR2AHTR2C | |
| SCHEMBL30200837 | 0.78 | HTR2A (0.33) | HTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL19504916 | 0.71 | — | — | |
| SCHEMBL1358786 | 0.71 | UCHL1 (0.41) | RORC | |
| SCHEMBL14857763 | 0.71 | — | — | |
| SCHEMBL1358313 | 0.68 | LRRK2 (0.40) | — | |
| SCHEMBL22516955 | 0.68 | MAPK1 (0.46) | CSNK2A1KDM4ECYP1A2LMNA | |
| SCHEMBL5390248 | 0.68 | ADORA2A (0.36) | MAP2K1CSNK2A1 | |
| SCHEMBL27395984 | 0.67 | CSNK2A1 (0.33) | MAP2K1CSNK2A1 | |
| Bromide SCHEMBL5386504 | 0.67 | ADORA2A (0.36) | MAP2K1CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569314-B1 | FUSED BICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICALS LLC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-09-26 | — | — | US | disclosed |
| US-8445510-B2 | Fused bicyclic kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2569314-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2011-11-17 | — | — | US | disclosed |
| WO-2011143645-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | ALK, RET, MET | MAP2K1 165/4885CSNK2A1 549/4885RORC 595/4885 |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | ALK, RET, MET | MAP2K1 165/4885CSNK2A1 549/4885RORC 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.